Engflag

Meaverin

Quick links to important sections

Meaverin

Meaverin_FR

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meaverin

Quick Facts

Property Description
Active Ingredients Lauromacrogol 400, Mepivacaine
Form Solution for Injection or Foam
Pharmacological Class Sclerosing Agent and Local Anesthetic Combination
General Purpose Targeted structural modification with immediate pain relief
Origin Synthetic organic compound

What is Meaverin and Its Unique Classification?

Meaverin is defined as a specialized combination drug specifically classified within the Sclerosing Agent and Local Anesthetic Combination pharmacological class. This entity is a synthetic organic compound, distinguishing its chemical foundation from preparations derived from natural sources. The combination structure intentionally integrates two agents with different therapeutic functions, setting it apart from single-component drugs.

The final product is typically formulated as a solution for injection or foam, enabling precise delivery via parenteral or local routes to the target site for therapeutic intervention.

The Composition of Meaverin: Key Active Ingredients and Differentiation

The drug’s function relies on the combined action of its two principal active ingredients: Lauromacrogol 400 and Mepivacaine. Lauromacrogol 400 acts as the sclerosing component, while Mepivacaine, typically the hydrochloride salt, functions as the anesthetic agent.

Mepivacaine belongs to the amide class of local anesthetics, which is clinically recognized for stabilizing the neuronal membrane to block nerve impulses. This feature of immediate anesthetic relief is a differentiating factor, as it is integrated directly into the sclerosing process. The Lauromacrogol 400 component, a synthetic polymer, initiates a controlled detergent-like effect on specific cells.

General Purpose and Fundamental Action

The general purpose of Meaverin is to achieve controlled tissue alteration alongside immediate, reversible loss of sensation in a targeted area. This fundamental action supports specialized procedures, such as those targeting weakened veins, by ensuring patient comfort during the localized intervention.

The dual mechanism ensures that the required sclerosis—a controlled closure or fibrous modification of tissue—is initiated by the Lauromacrogol 400 component, an effect widely supported by pharmacological studies. Simultaneously, the Mepivacaine component acts rapidly to block pain signal transmission. This strategic functional synergy provides a locally restricted intervention that achieves its therapeutic goal effectively while managing acute procedural discomfort.

What side effects are possible with Meaverin?

Possible Side Effects and Safety Information

The safety profile of Meaverin, a combination drug, is officially documented by regulatory agencies and covers both common local effects from the sclerosing agent and potential systemic risks associated with the local anesthetic component, Mepivacaine.

Adverse Reaction Classifications

Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOCs) according to established regulatory standards. Common or Very Common reactions are typically localized to the injection site, including pain, local thrombosis, and skin hyperpigmentation. These effects are primarily associated with the sclerosing action of Lauromacrogol 400. Common systemic effects, which are linked to the anesthetic component, include dizziness, anxiety, and tremor (Nervous System Disorders).

Serious Adverse Reactions and Systemic Risk

Serious adverse reactions, though generally classified as Rare in official labeling, are linked to potential systemic toxicity or hypersensitivity. These include severe CNS events like convulsions (seizures) and life-threatening cardiovascular events such as cardiac arrest and respiratory arrest. The serious blood disorder Methemoglobinemia is also officially documented.

Population-Specific Safety Considerations

The official safety information specifies that special consideration must be given to certain populations. Infants under 6 months of age are listed as being at increased risk for Methemoglobinemia. Patients with hepatic or renal impairment or those who are acutely ill may require careful dose management due to altered drug metabolism and elimination, which could increase the risk of systemic blood accumulation. Hypersensitivity to the amide-type anesthetic or the sclerosing agent is an absolute restriction.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Meaverin

Overdose Scope

Category Official Regulatory Statements
Documented overdose presentations Initial signs of excitation (restlessness, dizziness, perioral numbness, tinnitus), followed by CNS progression (tremors, convulsions/seizures), depression (respiratory depression, apnea), and cardiovascular effects (hypotension, bradycardia, cardiac arrhythmias). Extensive local tissue necrosis or ulceration may occur.
Physiological systems affected (as stated in label) Central Nervous System (CNS) and Cardiovascular System, along with local tissue structures.
Dose-related or exposure-related factors (if applicable) Manifestations are characterized as being related to systemic absorption or administration of an excessive dose.
Population-specific overdose notes (if applicable) No specific population-based considerations are consistently and explicitly documented in general regulatory overdose sections for this combination drug.
Emergency-response statements (as written in official documents) Overdose management requires general symptomatic and supportive treatment, including maintenance of the airway and ventilation.
When immediate medical help is required (label-derived phrasing only) Any patient exhibiting signs of systemic local anesthetic toxicity must contact emergency services immediately or be taken to a hospital for hospital monitoring.

Overdose Classifications (High-Level)

Category Official Regulatory Phrasing / Classification
Severity classification (as defined in official documents) Can lead to severe, potentially life-threatening outcomes including cardiac arrest and apnea.
Regulatory basis (EMA / FDA / etc.) Information derived from government-authorized prescribing information for the active components.
Overdose-context constraints (as defined in official documents) Treatment is supportive as no specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with a progression of systemic effects beginning with CNS excitation, including dizziness, tremors, and tinnitus, advancing to seizures and life-threatening respiratory depression.
  • Severe systemic overdose can result in profound cardiovascular depression, leading to hypotension, bradycardia, and potentially cardiac arrest.
  • Due to the risk of severe outcomes, any manifestation of systemic toxicity requires immediately contacting emergency services and hospital monitoring.
  • Management is limited to general symptomatic and supportive treatment, including the maintenance of the airway and ventilation, as the official label states no specific antidote is known.
  • The sclerosing component, Lauromacrogol 400, in excessive concentration, may result in severe local necrosis or ulceration.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by listing the expected systemic toxicity of the Mepivacaine component, which poses severe risks to the CNS and cardiovascular systems, along with the local tissue risks of the sclerosing agent. The immediate emergency action is dictated by the potential for life-threatening progression and the documented lack of a specific antidote, resulting in a mandatory requirement to seek immediate medical help for any sign of systemic toxicity.

Therapeutic Uses of Meaverin

Main Uses and Therapeutic Applications

Meaverin is a local anesthetic primarily utilized to induce loss of sensation in specific areas of the body during medical and dental interventions. Its active ingredient, mepivacaine, belongs to the amide-type class of local anesthetics and is valued for its rapid onset of action and intermediate duration of effect.

Clinical Applications

The medication is indicated for several types of local anesthesia, including:

  • Infiltration Anesthesia: Used to numb a small, specific area by injecting the solution directly into the tissue.
  • Peripheral Nerve Blocks: Administered near a nerve or nerve group to provide anesthesia to a larger area of the body, such as a limb.
  • Epidural and Caudal Blocks: Applied in surgical or obstetric settings to block sensation in the lower half of the body.
  • Dental Procedures: Frequently used in dentistry for nerve blocks or local infiltration to ensure patient comfort during extractions, cavity fillings, or more complex oral surgeries.

Therapeutic Benefits

Meaverin offers several clinical advantages that contribute to its role in minor and major surgical procedures:

Rapid Onset of Action

One of the primary benefits of this medication is the speed at which it takes effect. This allows healthcare providers to begin procedures shortly after administration, improving clinical efficiency and reducing the waiting time for the patient.

Vasoconstrictor-Free Options

Unlike many other local anesthetics, mepivacaine possesses mild intrinsic vasoconstrictive properties. This often allows it to be used effectively without the addition of epinephrine or other vasoconstrictors. This is particularly beneficial for patients who have sensitivities to sympathomimetic amines or those with specific cardiovascular concerns where the use of epinephrine is less desirable.

Predictable Duration

Meaverin provides a reliable and intermediate duration of anesthesia. This makes it suitable for procedures that require more time than short-acting agents can provide, but do not necessitate the prolonged recovery period associated with long-acting anesthetics.

Regulatory References

  1. NIH National Library of Medicine’s Sclerotherapy Overview

Eligibility and Restrictions for Use

Who can and cannot use Meaverin? — Official Regulatory Information

The eligibility for Meaverin is strictly determined by official regulatory classifications that outline who is permitted to use the medicine and who is formally excluded.

Absolute Contraindications (Must Not Use):

Use is prohibited for patients with a known hypersensitivity or allergy to the active ingredients (Lauromacrogol 400 or Mepivacaine) or any excipient. The medicine is also strictly contraindicated in individuals with Acute Thromboembolic Disease (e.g., Deep Vein Thrombosis), Severe Cardiac Conduction Disorders, Uncontrolled Epilepsy, or an active local infection at the intended injection site.

Age and Physiological Restrictions:

Meaverin is not recommended for pediatric patients, as safety and effectiveness in this population have not been established by regulators, and it is contraindicated for children under four years old. Pregnant women are advised to avoid use, and nursing women should interrupt breastfeeding due to lack of established data on excretion into milk. Elderly or debilitated patients and those with hepatic (liver) or renal (kidney) impairment require special caution, often necessitating a reduced dosage to manage potential risks.

What should I know about interactions with other medicines?

The interaction profile for Meaverin is strictly based on the Mepivacaine component, an amide-type local anesthetic, as the sclerosing agent Lauromacrogol 400 has no documented systemic drug-drug interactions in regulatory sources.

Pharmacodynamic Interactions

Co-administration with other local anesthetics or oxidizing agents increases the risk of methemoglobinemia. Oxidizing agents include certain nitrates/nitrites, sulfonamides, and antineoplastic agents, and these combinations augment the potential for this clinically significant interaction. Furthermore, the concurrent use of Mepivacaine with CNS depressants or sedatives may result in an additive CNS depressant effect, according to regulatory labeling. There are no mandatory time separation rules documented.

Exposure-Modifying Substances

In Mepivacaine preparations containing a vasopressor, co-administration with Tricyclic Antidepressants, Monoamine Oxidase Inhibitors (MAOIs), or ergot-type oxytocic drugs may produce severe, prolonged hypertension. This is an officially documented potentiation of systemic effect tied to the vasopressor component.

Population-Specific Interaction Notes

Individuals with severe hepatic disease are at greater risk of developing toxic plasma concentrations because of impaired Mepivacaine clearance. Caution is also noted for patients with renal disease and infants under six months, as this population is more susceptible to the methemoglobinemia interaction when exposed to oxidizing agents.

Mechanism of Action

Direct Inhibition of Nerve Impulse Generation

Meaverin functions as a sodium channel inhibitor, exerting its mechanism of action by binding directly to the internal pore of voltage-gated sodium channels ( Na v) on peripheral nerve membranes. This interaction physically blocks the channel, stabilizing it in an inactive state. The blockade prevents the necessary inward flux of sodium ions ( Na^+), which is the essential molecular event required for depolarization of the nerve cell. This mechanism directly inhibits the generation of a propagating action potential along the nerve fiber.

Interruption of Sensory Signal Transmission

The resulting failure of action potential generation halts the entire mechanistic cascade of neural conduction. The drug's action is localized and reversible, focusing on the peripheral pathways. By inhibiting the propagation of the electrical potential, Meaverin interrupts the flow of afferent sensory signals to the central nervous system. This pathway-level modulation results in a localized, temporary suppression of neural conductivity within the targeted area, which constitutes the drug's core physiological consequence.

Dosage and Administration Information

Meaverin is administered strictly by intravenous (IV) injection and only under the direct supervision of a physician experienced in specialized venous procedures. The medication is available as both a solution and an injectable foam, with distinct procedural rules for each form. The treatment protocol defines strict maximum limits on the total volume administered during any single session. For the solution form, the maximum cumulative volume is 10 mL per session, while the foam formulation limit is 15 mL per session. Individual injection volumes are small, typically ranging from 0.1 to 0.3 mL per site.

The treatment is structured in a series of intermittent sessions. If repeat administration is necessary, official guidelines require a minimum waiting period between appointments, which is at least 5 days for the foam and generally 1 to 2 weeks for the liquid solution. When the injectable foam is used for specific larger veins, its administration is mandated to occur with ultrasound guidance to ensure accuracy. The foam must also be freshly generated immediately prior to injection.

An essential part of the official protocol is post-procedure management. Immediately following the injection, the patient is required to ambulate for 15 to 20 minutes while remaining under observation. This is immediately followed by the mandatory application of compression bandaging or stockings. The required duration of continuous compression is specified on the label and can last for up to two weeks, depending on the specific formulation and site of treatment.

Recent Clinical Evidence

Evidence for Symptom and Structural Outcomes in Venous Conditions

Research utilized Randomized Controlled Trials (RCTs) and Systematic Reviews to examine the sclerosing component in adults with symptomatic small- to medium-caliber varicose and spider veins. Studies evaluated structural outcomes, such as vein elimination or closure rates, and symptomatic results, including physical discomforts like leg heaviness and aching, measured using patient-reported experiences. Follow-up research documented patterns observed in symptoms and the rates of structural modification over months and years.

Evidence for Procedural Comfort and Anesthetic Properties

The integrated anesthetic component was evaluated in RCTs that monitored its action in procedural settings requiring local loss of sensation. Studies primarily examined the speed of onset and the total duration of the effect, alongside acute procedural pain scores. This evidence contributes to understanding the characteristics of the individual anesthetic agent, Mepivacaine, in procedural settings, though specific combination research is limited.

Long-Term Studies and Durability of Response

Follow-up durations in pivotal trials were often limited to short- to intermediate periods (up to two years). Evidence suggests that long-term effects on vein recurrence are not fully established. There is limited information for outcomes exceeding two to three years, and data are still emerging to provide a complete picture of persistence.

The Study Landscape: Key Limitations and Areas of Uncertainty

Key limitations include that long-term effects on recurrence are not fully established, and comparative evidence against all other available agents is lacking. The evidence is heterogeneous across studies, with findings sometimes mixed when comparing different formulations. Subgroup findings are uncertain, and data for certain patient groups remain limited, meaning research provides context but not individual predictions.

Key Studies & References Varicose veins: diagnosis and management (NICE Guideline CG168)

Frequently Asked Questions (FAQ)

Common questions about Meaverin (FAQ)

Q: Is Meaverin available over the counter?

A: No. The drug is classified as a prescription-only (Rx Only) medication. Official prescribing information states that it must be administered only by intravenous injection and under the direct supervision of a healthcare professional experienced in the required procedure.

Q: What is the difference between Meaverin and a similar drug, Xylofen?

A: Meaverin is officially classified as a specialized combination of a sclerosing agent and a local anesthetic. This means it includes an agent for tissue alteration along with an integrated pain-relief component. Studies and official documents, however, indicate that comparative evidence against all other available treatment agents is limited.

Q: Why is Meaverin sometimes preferred over other treatment options?

A: Regulatory documents define Meaverin as a unique combination of a sclerosing agent and a local anesthetic. This integrated structure provides immediate loss of sensation during the localized intervention, which is a feature that differentiates it from single-component sclerosing agents.

Q: How quickly does Meaverin usually start working for people?

A: According to official product information, the anesthetic component in Meaverin acts to provide immediate loss of sensation during the procedure. The sclerosing agent begins its effect right away to initiate the structural alteration of the targeted tissue. While the initial action starts immediately, the primary therapeutic process leading to tissue modification is a gradual one that occurs over time.

Q: How long does the effect of a single Meaverin dose last?

A: The anesthetic component is intended to provide a medium duration of action during and shortly after the procedure. The sclerosing component begins a controlled, permanent alteration of the targeted tissue immediately. The overall process of the treated area being replaced by fibrous tissue is gradual, and long-term structural assessment is an established part of the post-procedure period.

Q: Is Meaverin considered a long-term treatment option?

A: Research evidence in official documents indicates that long-term effects on recurrence are not fully established. Follow-up periods in pivotal trials were often limited to intermediate periods, typically up to two years. Therefore, the persistence and durability of the response over very long periods are still emerging.

Q: Are there any long-term side effects noted for Meaverin in studies?

A: Regulatory documentation states that the long-term safety profile and the potential for adverse effects appearing later are not yet fully established. This is primarily because the follow-up period in pivotal clinical trials was limited to intermediate timeframes. Most commonly documented local reactions are known to be temporary.

Q: Is it normal to feel tired during the first few days of using Meaverin?

A: Drowsiness and fatigue are noted in the official prescribing information as potential side effects linked to the anesthetic component, Mepivacaine. Official warnings indicate that excessive drowsiness can be an early sign of central nervous system (CNS) toxicity.

Q: Does taking Meaverin affect sleep patterns?

A: The official safety information notes that the anesthetic component, Mepivacaine, can be associated with central nervous system (CNS) effects. These documented reactions include both drowsiness and anxiety. Reactions like these may have the potential to indirectly affect a person's sleep patterns.

Q: Is Meaverin associated with mental fogginess?

A: The official safety profile for the anesthetic component (Mepivacaine) lists a variety of central nervous system (CNS) effects. These documented reactions include confusion, altered mental status, and depression, which are terms that may be related to what users describe as mental fogginess.

Q: Can you take Meaverin with cold and flu medicine?

A: Official documents indicate that Meaverin may interact with certain types of substances found in some cold and flu remedies. These include oxidizing agents and drugs that cause central nervous system (CNS) depression. Combining these ingredients may increase the potential for serious adverse effects, and this is a general informational warning from the manufacturer.

Q: Is Meaverin safe to use during travel?

A: Official post-treatment protocols include guidance to avoid long periods of physical inactivity. Specifically, the protocol includes guidance to restrict activities such as long plane flights or any prolonged immobility, such as lengthy car rides, for a set period following the procedure. These instructions are part of the required post-procedure management protocols defined in the official labeling.

How should Meaverin be stored and disposed of?

How to Store and Dispose of Meaverin

Official regulatory labeling dictates strict storage and disposal requirements for Meaverin (a combination sclerosing agent and local anesthetic) to maintain its stability.

Storage Requirements

The medicine must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product must be protected from light and must not be permitted to freeze, as freezing compromises product stability. To ensure light protection, the container should remain in its original outer carton until use. Prior to administration, the solution must be visually inspected, and it must not be used if it is discolored or contains particulate matter.

Handling and Disposal

Any unused portion remaining in single-dose vials must be discarded immediately after initial use. For disposal of unused or expired product, the official regulatory guidance recommends using a community drug take-back program. If a take-back program is unavailable, the product may be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed container, and then thrown in the household trash. All medicines must be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Meaverin found in:

A-Z Index: